Medicines Co. (MDCO) Reports Q2 EPS of $2.51
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
The Medicines Company (MDCO) PT Raised to $55 at Guggenheim; Sees Multiple Avenues to Unlock Value
July 27, 2016 10:10 AM EDTGuggenheim analyst Louise Chen reiterated a Buy rating and lifted her price target on The Medicines Company (NASDAQ: MDCO) to $55.00 (from $45.00) following Q2 results. The analyst sees multiple avenue to unlock value ahead of potential catalysts in 2016+.
Chen commented, "2Q16 results underscore our positive investment thesis, in our view, because MDCO continues to advance its pipeline and has multiple strategic options available... More
